Eli Lilly and Company reports $65.18 billion revenue for fiscal year ended December 31, 2025, up 44.7%
Eli Lilly and Company reported revenue of $65.18 billion for the year ended December 31, 2025, an increase of 44.7% from the previous year ($45.04 billion).
For the same period it posted net income of $20.64 billion, up 94.9%, or $22.95 per diluted share (11.71 a year earlier).
That is a net margin of 31.7%.
On Sanad's AAOIFI Standard 21 screen, Eli Lilly and Company is currently compliant: interest-bearing debt is 3.7% of market capitalisation (limit 30%), and impure income is 0.2% of revenue (limit 5%).
Is Eli Lilly and Company halal?
See the full AAOIFI screening of Eli Lilly and Company
See the full AAOIFI screening of Eli Lilly and Company
Source: 10-K filed with the U.S. Securities and Exchange Commission on February 12, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.